Day: March 2, 2026

us corporate news

WhiteHorse Finance 2025 Annual Report: Portfolio Overview, Investment Activity, and Financial Performance

Minichart

March 2, 2026

WhiteHorse Finance, Inc. Reports Q4 and FY 2025 Results; Ann...

Continue Reading 0

us corporate news

Dyne Therapeutics Reports 2025 Financial Results and Advances in Duchenne and Myotonic Dystrophy Drug Development

Minichart

March 2, 2026

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 ...

Continue Reading 0

us corporate news

Paramount Skydance to Acquire Warner Bros. Discovery in $110 Billion Merger, Creating Global Media Powerhouse

Minichart

March 2, 2026

Paramount to Acquire Warner Bros. Discovery in Landmark \$11...

Continue Reading 0

us corporate news

Roblox Corporation 8-K SEC Filing Details – February 24, 2026

Minichart

March 2, 2026

Roblox Corporation 8-K Filing: Chief People and Systems Offi...

Continue Reading 0

us corporate news

DBV Technologies Reports Positive Phase 3 VITESSE Results for VIASKIN Peanut Patch in Children with Peanut Allergy at AAAAI 2026 123

Minichart

March 2, 2026

DBV Technologies Reports Positive Phase 3 VITESSE Study Data...

Continue Reading 0

us corporate news

Klaviyo, Inc. Files Form 8-K with SEC – Key Company and Stock Information (March 2, 2026)

Minichart

March 2, 2026

Klaviyo, Inc. Announces \$500 Million Share Repurchase Progr...

Continue Reading 0

us corporate news

TEGNA Reports 2025 Financial Results, Exceeds Guidance and Updates on Nexstar Acquisition Progress

Minichart

March 2, 2026

TEGNA Inc. Reports Q4 and Full-Year 2025 Results; Nexstar Ac...

Continue Reading 0

us corporate news

Strategy Inc Form 8-K Filing Details, Trading Symbols, and Security Listings for 2026

Minichart

March 2, 2026

Strategy Inc. (Formerly MicroStrategy) Issues Key Updates: A...

Continue Reading 0

us corporate news

Day One Biopharmaceuticals 2026 Outlook: OJEMDA Growth, Pipeline Updates & Financial Highlights

Minichart

March 2, 2026

Day One Biopharmaceuticals Reports Strong 2025 Results, Pipe...

Continue Reading 0

us corporate news

NewAmsterdam Pharma’s Obicetrapib Shows Promise for LDL-C Lowering, Cardiovascular Risk Reduction, and Alzheimer’s Disease – Clinical Data, Market Opportunity, and Patent Portfolio Overview

Minichart

March 2, 2026

NewAmsterdam Pharma (Nasdaq: NAMS) Investor Update: March 20...

Continue Reading 0